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ABSTRACT  
Galantamine hydrobromide is formulated in tablets and capsules prescribed through oral delivery for the treatment of Alzheimer’s disease. 
However, oral delivery of drugs can cause severe side effects such as nausea, vomiting, and gastrointestinal disturbance. In the present research 
work, Galantamine hydrobromide is formulated as proniosome gel by Coacervation phase separation method using different surfactants such 
as Tweens and Spans. Overall eight formulations were developed and evaluated for various parameters.  The prepared gels were viewed by 
naked eye to observe the colour of gel. Microscopical observations of the gels showed vesicles of optimum size from 3.030 m (P2) - 3.735 m 
(P5). The gel also showed optimum rate of spontaneity in the range 9.60 mm3x1000 (P7) to 11.80 mm3x1000 (P4) and entrapment efficiency of 
vesicles in the range 66.15% (P5) to 86.92% (P3). The gels had pH in suitable range of skin (5.92-6.9). The in vitro drug diffusion studies 
revealed that the drug diffusion was affected by the various surfactants used. The rank order of surfactant effect on in-vitro drug diffusion was 
Tween 80 > Tween 60 > Tween 40 >Tween 20 > Span 80 > Span 60 > Span 40 > Span 20. The proniosomal gel containing Tween 80 sho wed 
maximum drug diffusion (99.24%) and the gel containing Span 20 showed minimum drug diffusion (71.74%). FT-IR studies of optimized 
proniosome gel P8 revealed the absence of any chemical interactions between drug and carriers used.  
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Alzheimer's disease is a progressive disorder that causes 
brain cells to waste away (degenerate) and die. Alzheimer's 
disease is the most common cause of dementia-a continuous 
decline in thinking, behavioral and social skills that disrupts 
a person's ability to function independently. The early signs 
of the disease may be forgetting recent events or 
conversations [1]. While there are currently no treatments 
available to slow or stop the brain damage caused by 
Alzheimer’s disease, several medications can temporarily 
help improve the symptoms of dementia for some people. 
These medications work by increasing neurotransmitters in 
the brain [2]. The U.S. Food and Drug Administration (FDA) 
has approved two types of medications — cholinesterase 
inhibitors (Aricept®, Exelon®, Razadyne®) 
and memantine (Namenda®). 
Galantamine hydrobromide is a cholinesterase inhibitor that 
has been used to reverse the muscular effects of gallamine 
triethiodide and tubocurarine, and has been studied as a 
treatment for Alzheimer's disease and other central nervous 
system disorders. Galantamine hydrobromide has 
advantages such as lower muscarinic side effects and higher 
speed of recovery from respiratory depression, can 
penetrate through the blood-brain barrier, can bind to 
nicotinic acetylcholine receptors, and enhanced microglial 
amyloid-beta peptides phagocytosis. It is formulated in 
tablets and capsules, prescribed through oral delivery for the 
treatment of Alzheimer’s disease.   However, oral delivery of 
drugs can cause severe side effects such as nausea, vomiting, 
and gastrointestinal disturbance [3]. To avoid these side 
effects various novel drug delivery systems have been 
developed, which include noisomes, proniosomes, liposomes, 
nanoparticles, microspheres, micro-emulsions, implantable 
pumps and magnetic microcapsules[4].    
Proniosomes are vesicular systems, in which the vesicles are 
made up of non-ionic based surfactants, cholesterol and 
other additives. Semisolid liquid crystal gel (proniosomes) 
prepared by dissolving the surfactant in a minimal amount of 
an acceptable solvent, namely ethanol and then hydration 
with least amount of water to form a gel. These structures 
are liquid crystalline compact niosomes hybrids that can be 
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converted into niosomes immediately upon hydration or 
used as such in the topical/transdermal applications. 
Proniosomal gels are generally present in transparent, 
translucent or white semisolid gel texture, which makes 
them physically stable during storage and transport [5].  
OBJECTIVE 
The objective of present study is to formulate Galantamine 
hydrobromide proniosome gel using various surfactants and 
evaluate the prepared gels for topical delivery. 
MATERIAL AND METHODS 
Galantamine hydrobromide was obtained as a gift sample 
from Caplin Point Labs, Chennai. Span 20, 40, 60, 80 was 
purchased from Central Drug House, Mumbai and Tween 20, 
40, 60, 80, and cholesterol from S.D Fine Chemicals Pvt Ltd, 
Mumbai. Soya Lecithin was obtained from   Hi Media Lab, 
Mumbai. All other chemicals used were of analytical grade.   
Drug Characterisation 
Identification 
A 1000 µg/ml solution of Galantamine hydrobromide in 
phosphate buffer of pH 7.4 was scanned in UV range between 
200 to 400 nm to estimate the maximum absorbance of the 
drug and was noted. Standard Calibration Curve was 
prepared by preparing drug solutions of suitable 
concentrations in respective medium [6].  
Solubility studies 
Excess amount of the selected drug was taken and dissolved 
in a measured amount of distilled water and phosphate 
buffer of pH 7.4 separately in a glass beaker to get a 
saturated solution. The solution was shaken intermittently to 
assist the attainment of equilibrium with the undissolved 
drug particles. Then measured quantity of the filtered drug 
solution was withdrawn after 24 hrs and successively diluted 
with respective solvents and the concentration was 
measured spectrophotometrically [7, 8]. 
Partition coefficient 
A drug solution of 1mg/ml was prepared in n-octanol. 25 ml 
of this solution was taken in a separating funnel and shaken 
with an equal volume of phosphate buffer of pH 7.4 (aqueous 
phase) for 10 min and allowed to stand for two hrs. Then 
aqueous phase and organic phase were collected separately. 
Both the phases were analyzed for the drug concentration 
using U.V. spectrophotometer. Partition coefficient was 
calculated by taking the ratio of the drug concentration in n-
octanol to drug concentration in aqueous phase [9, 10]. 
Permeability coefficient 
 The permeability coefficient of drug was calculated by “Potts 
and Guy equation” [11],  
                           
  
 
–                 ----(1)   
  Where,    LogKp = Permeability coefficient  
                   Ko/w     = Partition coefficient 
Formulation of Proniosome gel  
Proniosome gel was prepared by a coacervation-phase 
separation method (Fig.1). Precisely weighed amounts of 
surfactant, lecithin, cholesterol and drug were taken in a 
clean and dry wide mouthed glass vial of 5.0 ml capacity and 
alcohol (0.25 ml) was added to it. After warming, all the 
ingredients were mixed well with a glass rod; the open end 
of the glass bottle was covered with a lid to prevent the loss 
of solvent from it and warmed over water bath at 60-70°C 
for about 5 min until the surfactant mixture was dissolved 
completely. Then the aqueous phase (pH 7.4 phosphate 
buffer solution) was added and warmed on a water bath till a 
clear solution was formed which was converted into 
proniosome gel on cooling. The gel so obtained was 
preserved in the same glass bottle in dark conditions for 
characterization [12]. The composition of various proniosome 
gels in given in Table 1.  
 
 
Figure 1: Diagrammatic representation of Proniosome gel preparation
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Evaluation of proniosome gel 
The Galantamine hydrobromide proniosome gel 
formulations were evaluated for the following parameters: 
Morphological evaluation 
The prepared gels were viewed by naked eye to observe the 
colour of gel and appearance.  
Vesicle Size analysis:  Hydration of proniosome gel (100 
mg) was done by adding saline solution (0.9% solution) in a 
small glass vial with occasional shaking for 10 min. The 
dispersion was observed under optical microscope at 45 x 
magnification. The sizes of 200 - 300 vesicles were 
measured using a calibrated ocular and stage micrometer 
fitted in the optical microscope.  
 





       Surfactant                    Weight 










P1 10 Span 20 (S20) 180 180 20 0.25 0.16 
P2 10 Span 40 (S40) 180 180 20 0.25 0.16 
P3 10 Span 60 (S60) 180 180 20 0.25 0.16 
P4 10 Span 80 (S80) 180 180 20 0.25 0.16 
P5 10 Tween 20 (T20) 180 180 20 0.25 0.16 
P6 10 Tween 40 (T40) 180 180 20 0.25 0.16 
P7 10 Tween 60 (T60) 180 180 20 0.25 0.16 
P8 10 Tween 80 (T80) 180 180 20 0.25 0.16 
 
 
Rate of spontaneity:  10 to 20 mg of proniosome gel was 
transferred to the bottom of a clean stopper glass bottle and 
spread uniformly around the wall of the glass bottle with the 
help of a glass rod. At room temperature, 2 ml of phosphate 
saline (0.154 M Sodium chloride) was added carefully along 
the walls of the glass bottle and left in a test-tube stand. After 
20 min, a drop of this saline solution was withdrawn and 
placed on Neubauers Chamber to count the number of 
vesicles. The number of niosomes eluted from proniosomes 
was counted [13].  
% Entrapment efficiency:  To evaluate the loading capacity 
of proniosome systems proniosome gel (100 mg) was 
dispersed in phosphate buffer pH 7.4 and warmed a little for 
the formation of niosomes. Then the dispersion was 
centrifuged at 9000 rpm for 30 min at 20oC. The clear 
fraction was used for the determination of free drug at 289 
nm spectrophotometrically[14]. The percentage entrapment 
efficiency was calculated from following Equation. 
% Entrapment efficiency = [Total drug- Free drug / Total 
drug] x 100-------- (2) 
pH determination: The pH of each Proniosome gel was 
determined using pH meter. The electrode was first 
calibrated with pH 4.0 and pH 7.0 solutions then sample 
readings were recorded on pH meter [15].   
In-vitro diffusion studies:  In vitro diffusion studies on 
proniosome gel were performed using Franz-diffusion cell. 
The capacity of receptor compartment was 40 ml. The 
dialysis cellophane membrane was mounted between the 
donor and receptor compartment. A weighed amount of 
proniosome gel equivalent to 4 mg (152 mg of gel) was 
placed on the donor compartment side.  The receptor 
medium was phosphate saline buffer pH 7.4[16]. Heat was 
provided using a thermostatic hot plate with a magnetic 
stirrer. The receptor fluid was stirred by a Teflon-coated 
magnetic bead fitted to a magnetic stirrer. At each sampling 
interval i.e., every hour, 1 ml of sample was withdrawn and 
replaced with 1 ml fresh buffer to maintain sink condition. 
Samples withdrawn were analyzed spectrophotometrically 
at 289 nm. 
Fourier transformer infrared spectroscopy (FTIR) study 
For establishing compatibility of drug and excipients several 
methods are being used. Most commonly used are 
spectroscopic studies like IR, HNMR, Mass, differential 
scanning calorimetry (DSC), X- ray diffraction etc. In the 
present study we have utilized values of IR spectra. 
RESULTS AND DISCUSSION 
Drug characterisation 
Identification 
The absorption maximum was found to be 289 nm in 
phosphate buffer of pH 7.4 which was in accordance with the 
literature reports (Table 2). 
Solubility 
The available literature on solubility profile of Galantamine 
hydrobromide indicated that the drug is sparingly soluble in 
water, and very slightly soluble in anhydrous ethanol.  
However, to mimic the physiological conditions of the skin, 
phosphate buffer pH 7.4 was used as the diffusion medium.    
The solubility was found to be 2.1 mg/ml in water with 
neutral pH and 2.2 mg/ml in phosphate buffer pH 7.4. The 
results of solubility studies are given in Table 2. 
Partition coefficient 
Partition coefficient is a measure of distribution of molecules 
between two phases. For transdermal delivery studies of 
partition coefficient between n-octanol and water is often used as 
a guide as to how well a molecule will distribute between 
stratum corneum lipids and water.  n-octanol gives a partition 
coefficient range consistent with the physical properties of 
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stratum corneum compared to other solvents. Phosphate buffer 
pH 7.4 was used to get absolute Kºw. The partition coefficient of 
drug Galantamine hydrobromide (1 mg/ml) between n-octanol 
and phosphate buffer pH 7.4 (aqueous phase) was found to be 
Kºw =1.44 (Table 2). Since Kºw value is less than 3, the drug will 
traverse the stratum corneum exclusively by intercellular 
pathway (9, 10). 
Permeability coefficient 
Permeability coefficient describes the rate of drug transport per 
unit concentration (cm/hr).The permeability coefficient of drug 
according to “Potts and Guy equation” was found to be 4.835 
cm/hr (Table 2). 
 












buffer pH 7.4 
Results 289 2.1 2.2 1.44 4.835 
Reported[4,17] 289 1.7 - 1.39 - 
 
Evaluation of proniosome gel 
Morphological evaluation 
The colour of the prepared proniosome gel formulations was 
observed by naked eye and the results are given in Table 3. 
The proniosome gel formulations showed brown and yellow 
colour depending on their chemical compositions. 
Proniosome gels P1 and P2 when viewed by optical 
microscope at 45 × magnification, showed spherical and 
discrete shaped vesicles with sharp boundaries. The 
observation is given in Fig. 2. 
Vesicle size analysis 
Determination of vesicle size is important for the topical 
application of vesicles. Brain et al demonstrated that vesicle 
more than 10 micrometer remains on skin surface and the 
vesicle of 3-10 micrometer concentrates in follicle and less 
than 3 micrometer penetrates the stratum corneum(18). 
Results of Vesicle size of Galantamine hydrobromide 
proniosome gel formulations are presented in Table 3. The 
Vesicle size of different formulations ranged from 3.030 µm 
(P2) to 3.735 µm (P5) indicating that vesicles formed could 
easily penetrate the stratum corneum. It was observed that 
Vesicles formed with Span as surfactant (P1 – P4) were 
smaller in size than vesicles formed with Tweens (P5 – P8); 
this was attributed to the fact that Spans have greater 
hydrophobicity than Tweens. It is indicated that increase in 
hydrophobicity decreases surface energy of surfactants 
resulting in smaller vesicle size.   
Rate of spontaneity studies 
Rate of spontaneity is the number of niosomes formed after 
hydration of proniosomes for 20 mins. The results of study 
are given in Table 3. Rate of spontaneity for different 
proniosome gel formulations were varied between 9.60 
mm3×1000 (P7) to 11.80 mm3×1000 (P4). Proniosome 
formulations prepared with Spans formed niosomes more 
spontaneously than Tweens. It was also observed that as the 
vesicle size decreased the rate of spontaneity increased.  
Entrapment efficiency (%) 
Vesicle entrapment efficiency mainly depends on the type of 
surfactant used, amount of surfactant required to form the 
bilayer and intrinsic properties of surfactants like HLB value, 
chemical structure, liphophilicity, phase transition 
temperature and alkyl chain length. It was found that 
surfactants which had low HLB value, higher liphophilicity, 
higher phase transition temperature and longer alkyl chain 
length showed higher entrapment. The results obtained were 
quite similar to the above discussion. The entrapment 
efficiency of all formulations was in the range of 66.15% (P6) 
to 86.92% (P3) as depicted in Table 3. The proniosome gels 
prepared with Spans (P1 –P4) as surfactants gave higher 
entrapment efficiency than Tweens (P5 – P8) because of 
smaller size of vesicles and higher lipophilic nature of spans 
than tweens. 
 
Table 3: Evaluation of Galantamine hydrobromide proniosome gel formulations  
Sl. No. Formulation 
code 






1 P1 Brown 3.315 11.75 78.00 6.9 
2 P2 Yellow 3.030 10.70 80.00 6.84 
3 P3 Yellow 3.233 10.90 86.92 6.32 
4 P4 Yellow 3.195 11.80 77.69 6.43 
5 P5 Brown 3.735 9.91 66.15 6.70 
6 P6 Brown 3.712 9.72 69.23 6.61 
7 P7 Brown 3.630 9.60 76.53 5.92 
8 P8 Brown 3.495 10.52 76.92 6.52 
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Proniosome gel P1 Proniosome gel P2 
Fig. 2: Optical photomicrograph of Galantamine hydrobromide proniosome gel P1 and P2. 
 
Among the proniosome gels prepared with Spans the 
entrapment efficiency was in the order Span 60 (P3) > Span 
40 (P2) > Span 20 (P1) > Span 80 (P4).  Span 60 showed 
higher entrapment efficiency than others. The entrapment 
efficiency of Span 80 (P4 -77.69%) formulation was less than 
that of Span60 (P3-86.92%). This was due to the reason that 
Spans 60 and 80 have the same head group, but Span 80 has 
an unsaturated alkyl chain that is responsible for low drug 
entrapment. 
pH determination 
The pH of each Proniosome gel was determined using pH 
meter. The pH was determined in order to investigate the 
possibility of any side effects in-vivo due to acidic or 
alkaline pH which may irritate the skin. The pH was found 
in between 5.92 (P7) to 6.9 (P1) which was well within the 
physiological skin surface pH (19) (Table 3). Changes in pH 
are reported to play an important role in the pathogenesis 
of skin diseases. Maintaining the skin pH helps maintain a 
proper balance of the “acid mantle” which aids in protecting 
the body from bacteria and helps prevent moisture loss (20). 
In- vitro diffusion study 
The in-vitro diffusion studies were conducted for all the 8 
formulations prepared. All proniosome gels delivered the 
drug for a period of 360 mins. The proniosome gels 
prepared with different Spans as surfactants i.e., P1(S20), P2 
(S40), P3 (S60) and P4 (S80) released 71.74%, 73.30%, 
74.55% and  77.85% of drug respectively at the end of 360 
mins. The proniosome gels prepared with different Tweens 
as surfactants i.e., P5 (T20), P6 (T40), P7 (T60) and P8 (T80) 
released 78.55%, 81.35%, 90.77% and 99.24% of drug at the 
end of 360 mins. The results are given in Fig. 3 and 4. It was 
evident from the results that proniosome gels prepared with 
Tweens gave a higher release than Spans. This is because 
Tweens are more hydrophilic, having higher HLB value, 
shorter alkyl chain length and low phase transition 
temperature than Spans. The drug being lipophilic favors 
more partition in the proniosome gel in case of spans and 
hence less drug is released from span formulations than 
tweens.
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Fig. 3: In-vitro diffusion profiles of proniosome gel formulations (P1 to P4) 
 
Fig. 4: In-vitro diffusion profiles of proniosome gel formulations (P5 to P8) 
 
Fourier transformer infrared spectroscopy (FTIR) study 
For establishing compatibility of drug and excipients IR 
spectra was used. It was evident from the values of IR 
spectra of pure drug and its formulations (P8) Tween 80 
(Fig. 5 & 6) that there is much resemblance in the spectra of 
drug and its formulation and it is almost identical in nature 
without showing much shift in the positions of characteristic 
absorption bands. This is possible only when drug remains in 
its normal form even after it is used for preparing 
formulations with carriers and other excipients. Since there 
is no appreciable change in the positions of characteristic 
absorption bands of different groups and bonds present in 
the drug molecule and its formulation it was concluded that 
drug has not reacted with the carriers and other excipients 
suggesting that there is no interaction of the drug.
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Fig. 6: FTIR spectra of optimized Galantamine hydrobromide proniosome gel- (P8) 
 
CONCLUSION 
In conclusion it can be stated that Galantamine 
hydrobromide was successfully developed in to proniosome 
gel for transdermal delivery. The adopted method i.e., 
coacervation-phase separation method yielded uniform and 
reproducible proniosome gel with the surfactants used. The 
surface morphology, vesicle size, rate of spontaneity, 
entrapment efficiency, and pH and in-vitro diffusion studies 
were uniform. Proniosome gel has the potential as an 
alternative dosage form in treating Alzheimer’s disease. 
Further studies are needed to investigate their invivo 
performance on suitable models. 
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